Compare Glenmark Pharma with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TTK HEALTHCARE - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA TTK HEALTHCARE GLENMARK PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 10.6 17.3 61.0% View Chart
P/BV x 1.5 1.4 108.9% View Chart
Dividend Yield % 0.7 1.1 59.8%  

Financials

 GLENMARK PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
TTK HEALTHCARE
Mar-19
GLENMARK PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs7121,215 58.6%   
Low Rs484610 79.3%   
Sales per share (Unadj.) Rs349.6444.4 78.7%  
Earnings per share (Unadj.) Rs32.817.2 190.1%  
Cash flow per share (Unadj.) Rs44.327.6 160.5%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.30.5 61.1%  
Book value per share (Unadj.) Rs198.6177.9 111.6%  
Shares outstanding (eoy) m282.1714.13 1,997.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.1 83.2%   
Avg P/E ratio x18.252.9 34.5%  
P/CF ratio (eoy) x13.533.0 40.8%  
Price / Book Value ratio x3.05.1 58.7%  
Dividend payout %6.129.0 21.0%   
Avg Mkt Cap Rs m168,62512,894 1,307.7%   
No. of employees `00012.02.3 520.6%   
Total wages/salary Rs m20,5611,307 1,573.1%   
Avg. sales/employee Rs Th8,196.02,715.7 301.8%   
Avg. wages/employee Rs Th1,708.1565.3 302.2%   
Avg. net profit/employee Rs Th768.5105.4 729.0%   
INCOME DATA
Net Sales Rs m98,6556,279 1,571.2%  
Other income Rs m2,08178 2,685.6%   
Total revenues Rs m100,7366,356 1,584.8%   
Gross profit Rs m15,858496 3,199.8%  
Depreciation Rs m3,259147 2,221.6%   
Interest Rs m3,34634 9,899.1%   
Profit before tax Rs m11,335393 2,887.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,756149 2,522.8%   
Profit after tax Rs m9,250244 3,795.6%  
Gross profit margin %16.17.9 203.6%  
Effective tax rate %33.137.9 87.4%   
Net profit margin %9.43.9 241.6%  
BALANCE SHEET DATA
Current assets Rs m66,9682,717 2,464.6%   
Current liabilities Rs m40,2111,571 2,559.9%   
Net working cap to sales %27.118.3 148.5%  
Current ratio x1.71.7 96.3%  
Inventory Days Days8332 259.1%  
Debtors Days Days8147 174.0%  
Net fixed assets Rs m33,322991 3,362.4%   
Share capital Rs m282141 199.7%   
"Free" reserves Rs m55,7702,373 2,350.2%   
Net worth Rs m56,0522,514 2,229.3%   
Long term debt Rs m35,7383 1,051,102.9%   
Total assets Rs m132,8884,158 3,195.9%  
Interest coverage x4.412.6 34.8%   
Debt to equity ratio x0.60 47,149.0%  
Sales to assets ratio x0.71.5 49.2%   
Return on assets %9.56.7 142.0%  
Return on equity %16.59.7 170.3%  
Return on capital %17.816.9 105.2%  
Exports to sales %03.6 0.0%   
Imports to sales %00.5 0.0%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs mNA31 0.0%   
Fx inflow Rs m62,998225 27,974.4%   
Fx outflow Rs m22,85971 32,145.4%   
Net fx Rs m40,140154 26,049.6%   
CASH FLOW
From Operations Rs m13,242173 7,649.7%  
From Investments Rs m-6,99097 -7,243.4%  
From Financial Activity Rs m-7,387-307 2,404.0%  
Net Cashflow Rs m-2,971-38 7,880.1%  

Share Holding

Indian Promoters % 48.3 65.4 73.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 3.7 186.5%  
FIIs % 34.4 5.2 661.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 25.8 40.7%  
Shareholders   56,727 12,723 445.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  WOCKHARDT  AUROBINDO PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - DR. REDDYS LAB COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS